Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMD3100 and Pembrolizumab in Advanced Head and Neck Cancer
NCT04058145Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of plerixafor in head and neck squamous cell carcinoma (HNSCC), sponsored by Massachusetts General Hospital. Planned start Sep 2019; status: withdrawn.
02
Drugs
plerixafor
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04058145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058145.